OHB Pediatrics

OHB Pediatrics, a subsidiary of Oak Hill Bio, is a clinical-stage biotechnology company dedicated to developing therapies for rare pediatric and neonatal diseases. The company's lead program is rugonersen (OHB-724), an antisense oligonucleotide (ASO) acquired from Roche, which is currently in Phase 3 development for the treatment of Angelman syndrome. OHB Pediatrics also advances OHB-607 (mecasermin rinfabate), a recombinant human IGF-1/IGFBP-3 complex, in Phase 2b trials to prevent complications of extreme prematurity, such as bronchopulmonary dysplasia. The company follows a strategic model of acquiring high-potential, deprioritized assets from major pharmaceutical companies like Roche and Takeda to accelerate their path to commercialization. Headquartered in the United Kingdom and supported by its parent company in the US, OHB Pediatrics is led by a team of industry veterans with extensive experience in rare disease drug development.